Jabbour, E., Morris, V., Kantarjian, H., Yin, C. C., Burton, E., & Cortes, J. (2012). Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. American Society of Hematology.

Jabbour, Elias, Van Morris, Hagop Kantarjian, Cameron C. Yin, Elizabeth Burton, and Jorge Cortes. Characteristics and Outcomes of Patients With V299L BCR-ABL Kinase Domain Mutation After Therapy With Tyrosine Kinase Inhibitors. American Society of Hematology, 2012.

Jabbour, Elias, et al. Characteristics and Outcomes of Patients With V299L BCR-ABL Kinase Domain Mutation After Therapy With Tyrosine Kinase Inhibitors. American Society of Hematology, 2012.